PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)
Gambardella V, Cervantes A, Bedard P, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Oliveira M, Saura C, Schmid P, Turner N, Varga A, Liu B, Chen J, Aimi J, Royer-Joo S, Schutzman J, Hutchinson K. PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC). Annals Of Oncology 2020, 31: s381-s382. DOI: 10.1016/j.annonc.2020.08.438.Peer-Reviewed Original Research